|
C12ORF32 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64859999984834E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.74290000052058E-07 |
| Normal-vs-Stage2 |
6.180600E-04 |
| Normal-vs-Stage3 |
1.976260E-04 |
| Normal-vs-Stage4 |
4.163600E-04 |
| Stage1-vs-Stage2 |
5.600400E-01 |
| Stage1-vs-Stage3 |
6.042800E-01 |
| Stage1-vs-Stage4 |
7.017400E-01 |
| Stage2-vs-Stage3 |
3.961800E-01 |
| Stage2-vs-Stage4 |
4.702600E-01 |
| Stage3-vs-Stage4 |
9.432400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.89310000009435E-07 |
| Normal-vs-AfricanAmerican |
5.526100E-02 |
| Normal-vs-Asian |
1.168190E-04 |
| Caucasian-vs-AfricanAmerican |
4.967800E-01 |
| Caucasian-vs-Asian |
8.928400E-01 |
| AfricanAmerican-vs-Asian |
4.727000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.53890000000168E-05 |
| Normal-vs-Female |
1.71800000003941E-07 |
| Male-vs-Female |
5.788200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.80370000005359E-06 |
| Normal-vs-Age(41-60Yrs) |
8.77670000010156E-07 |
| Normal-vs-Age(61-80Yrs) |
5.800600E-04 |
| Normal-vs-Age(81-100Yrs) |
2.906400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.812000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.453200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.825900E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.618600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.725700E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.754770E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.472800E-01 |
| Classical-VS-Follicular |
1.016460E-04 |
| Classical-VS-Other |
2.019400E-01 |
| Classical-VS-Normal |
9.03130015217357E-10 |
| Tall-VS-Follicular |
1.119360E-01 |
| Tall-VS-Other |
4.617200E-01 |
| Tall-VS-Normal |
1.783970E-03 |
| Follicular-VS-Other |
8.333600E-01 |
| Follicular-VS-Normal |
1.676560E-01 |
| Other-VS-Normal |
2.833400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.69040000000243E-05 |
| Normal-vs-N1 |
4.322300E-03 |
| N0-vs-N1 |
7.508800E-01 |
|
|
